Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
zgy5bbNGdQLEpAQg
